<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00493337</url>
  </required_header>
  <id_info>
    <org_study_id>NL18496.041.07</org_study_id>
    <nct_id>NCT00493337</nct_id>
  </id_info>
  <brief_title>A Community Pharmacist-led Intervention to Improve Adherence to Lipid-lowering Treatment</brief_title>
  <official_title>A Community Pharmacist-led Intervention to Improve Adherence to Lipid-lowering Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Utrecht Institute for Pharmaceutical Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Service Apotheek BV</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Harvard University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Department of Clinical Pharmacy, University Medical Centre St Radboud, The Netherlands.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Scientific Institute for Dutch Pharmacists, The Netherlands</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Federation of Patients and Consumer Organisations in the Netherlands</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Utrecht Institute for Pharmaceutical Sciences</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of the study is to test the effectiveness of a community pharmacist-led
      intervention to increase adherence to lipid lowering treatment.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Medication non-adherence represents an important threat to the health of the Western people.
      A large number of pharmacy records based studies demonstrated that adherence to lipid
      lowering treatment in daily practice is substantially worse compared to adherence observed in
      the controlled setting of randomized controlled trials. In addition, the relationship between
      non-adherence with statin-treatment assessed with pharmacy records and cardiovascular
      outcomes has been convincingly demonstrated. This implies that pharmacy records can and
      should be used to identify non-adherent patients and thus patients at risk for major
      cardiovascular events. Using this data, community pharmacists can play a more substantive
      role in developing the concept of pharmaceutical care. The objective of the study is to test
      the effectiveness of a community pharmacist-led intervention to increase adherence to lipid
      lowering treatment.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2008</start_date>
  <completion_date type="Actual">March 2010</completion_date>
  <primary_completion_date type="Actual">March 2010</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The primary outcome will be mean differences in adherence over 365 days after randomization by comparing the two intervention groups with the control group.</measure>
    <time_frame>one year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean differences in adherence over 180 days after randomization by comparing the two intervention groups with the control group.</measure>
    <time_frame>180 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean differences in adherence over 270 days after randomization by comparing the two intervention groups with the control group.</measure>
    <time_frame>270 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>If the pre-specified effect on mean adherence is measured, change in LDL-C will also be assessed.</measure>
    <time_frame>365 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complete discontinuation defined as more than 182 consecutive days of the one year observation period uncovered (&lt;50%).</measure>
    <time_frame>one year</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">373</enrollment>
  <condition>Hypercholesterolemia</condition>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Advanced counseling</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Compliance Card only</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>advanced adherence counseling+reminder</intervention_name>
    <arm_group_label>Advanced counseling</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Compliance Card</intervention_name>
    <arm_group_label>Compliance Card only</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Suboptimal adherent to statin treatment

          -  Older than 65 years

          -  Responsible for own medication intake

        Exclusion Criteria:

          -  Life expectancy shorter than 6 months

          -  Institutionalized

          -  User of medication blisters
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boris LG Van Wijk, PharmD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Pharmacoepidemiology &amp; Pharmacotherapy, Utrecht Institute for Pharmaceutical Sciences, Utrecht University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Anthonius De Boer, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Department of Pharmacoepidemiology &amp; Pharmacotherapy, Utrecht Institute for Pharmaceutical Sciences, Utrecht University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Olaf H Klungel, PharmD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Department of Pharmacoepidemiology &amp; Pharmacotherapy, Utrecht Institute for Pharmaceutical Sciences, Utrecht University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>William H Shrank, MD, MSHS</last_name>
    <role>Study Chair</role>
    <affiliation>Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Peter AG De Smet, PharmD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Scientific Institute of Dutch Pharmacists, The Hague</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Eibert R Heerdink, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Department of Pharmacoepidemiology &amp; Pharmacotherapy, Utrecht Institute for Pharmaceutical Sciences, Utrecht University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Emma Giesen, PharmD</last_name>
    <role>Study Chair</role>
    <affiliation>Service Apotheek BV</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Marnix Westein, PharmD</last_name>
    <role>Study Chair</role>
    <affiliation>Federation of Patients and Consumer Organisations in the Netherlands, Utrecht, The Netherlands</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Martina Teichert, PharmD</last_name>
    <role>Study Chair</role>
    <affiliation>Scientific Institute of Dutch Pharmacists, The Hague, The Netherlands</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Service Apotheek BV</name>
      <address>
        <city>Enter</city>
        <zip>7468 ZG</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>June 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 27, 2007</study_first_submitted>
  <study_first_submitted_qc>June 27, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 28, 2007</study_first_posted>
  <last_update_submitted>June 24, 2010</last_update_submitted>
  <last_update_submitted_qc>June 24, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 28, 2010</last_update_posted>
  <responsible_party>
    <name_title>BLG van WIjk</name_title>
    <organization>Utrecht Institute for Pharmaceutical Sciences, Utrecht University</organization>
  </responsible_party>
  <keyword>Adherence</keyword>
  <keyword>Compliance</keyword>
  <keyword>Statins</keyword>
  <keyword>Intervention</keyword>
  <keyword>Hypercholesterolemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypercholesterolemia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

